Index

ACASI, 100
ADAM. *See* Arrestee Drug Abuse Monitoring program
ADD. *See* Attention Deficit Disorder
AIDS. *See* HIV
analgesics, 18
analytic epidemiology, 10–11. *See also* descriptive epidemiology
antisocial behavior, 53
antisocial personality disorder, 21, 22
antisociality risk factor, drug abuse and, 21
anxiolytics, 18
archival data (epidemiological method), 63–76
  CEWG example, 72
    contributions to drug abuse epidemiologic methods, 75
    drug use patterns' time-space relationship, 75
    emergent trends, 74
    generating research questions, 75
  data sources, 65
    drug treatment programs, 67
    existing data limitations, overcoming of, 71
    hospital admissions and emergency department logs, 68
    law enforcement, 70
    medical examiners/coroners reports, 70
    poison control reports, 69
    public health reports of infectious diseases, 69
Arrestee Drug Abuse Monitoring program, 30
ASPD. *See* antisocial personality disorder
Attention Deficit Disorder (ADD), 16
autonomy principle, 148

back-calculation method, 127
beneficence principle, 149
biased networks, 92
biases, 84, 85
biomedical research (human), ethical requirements of, 149–51
blood pressure measurement, 6
brain imaging technologies, 5

campus surveys, 103–5. *See also* school surveys
cannabis, 18, 163
CAPI, 100
capture recapture method, 122–25. *See also* multiplier method
CD/ASPD. *See* conduct disorder/antisocial personality disorder
Central Registry of Drug Abuse, 169
CEWG. *See* Community Epidemiology Work Group
chain referral sample, 91. *See also* snowball sampling
  nomination rules factors, 94
  recuitment factor, 93
  waves factor, 93
Client Oriented Data Acquisition Process (CODAP), 227, 228
closed population, 125
cocaine, 18, 33, 163

Community EpidemiologyWork Group (CEWG), 9, 72–76, 171
  contributions to drug abuse epidemiologic methods, 75
  drug use patterns
    emergent trends in, 74
    time-space relationship, 75
  research questions, 75
conduct disorder/antisocial personality disorder, 21
confidentiality based ethical issues, 150, 154
criminal career concept, 31

data collection. *See also* population surveys
  guiding principles of (The Lisbon Consensus), 173
  triangulation technique, 140
DAWN. *See* Drug Abuse Warning Network
DCMADS, 231
dependence, 17, 19
  criteria, 5
  measures, 6
descriptive epidemiology, 9–10. *See also* analytic epidemiology
developing countries, drug epidemiological research challenges in, 154
Diagnostic and Statistical Manual of Mental Disorders, 5
drug abuse, 3, 17–20. *See also* drug use; drug use and abuse; epidemiology
  criteria for dependence and, 5
  defined, 4
  definitions, 5
  dependence measures, 6
  epidemiologic studies implications, 8–11
  ethical considerations for, 145–55
  natural cessation of, 6
  physiological problems and, 5
  qualitative methods in, 133–42
  risk factors, 20–23
  substance abuse and heterogeneity, 15–17
  treatment programs, long-term, 199
Drug Abuse and Control Act of 1970, 167
drug abuse prevention, 211
  epidemiological information linking with
    age of onset, 217
    needs assessments and program evaluation, 219–21
    principles of prevention (NIDA, 2003), 215
    risk and protection, 218
    sequencing of substance use, 218
  progamming and research, 212–15
    defining drug abuse prevention, 212
    in the U.S., 213–15
Drug Abuse Reporting Program (DARP), 227
Drug Abuse Treatment Outcome Study (DATOS), 227, 228
Drug Abuse Warning Network, 30, 170
drug control, 165
  drug information systems, 171
  drug monitoring elements, 167–70
  international conventions on narcotics control and global reporting obligations, 166
  multi-indicator models, 171
  networks, 171
drug information systems, 171
drug misuse. *See* drug abuse
drug monitoring elements, 167–70
drug treatment programs (archival data source), 67
drug use. *See also* drug abuse; drug use and abuse
  consequences
    antisocial behavior, 53
    health-related, 50
    interpersonal relationships, 54
    mental health-related, 51
  defining the role of, 47
  epidemiological research, nature of, 146
  ethical challenges in
    developing countries, challenges in, 154
    free and informed consent, 151
    privacy, confidentiality and legal hazard, 153, 154
    safety issues, 154
  ethics importance in, 147
  gender differences and, 37
  methodological issues, 48–50
    long-term consequences, 48
    short-term consequences, 48
  natural history of, 29
  population surveys for data collection, 99–106
  racial/ethnic differences and, 38

drug use and abuse, 46. *See also* drug abuse; substance use and abuse
  broad-based models, 178
    epidemiologic approach, 179
    personality approach, 180
    problem behavior approach, 180
    psychopathology approach, 181
    social adaptation approach, 179
  dependence criteria, 5
  longitudinal studies of, 178
  measuring of, 6–8
  models of predictive effects, 187
  protective factors, 187
  research scope, 188
  risk factors, 186
  theory-testing studies
    high-risk samples, 183–84
    minority samples, 184–85
    social learning models, 182–83
    temperament and self-control models, 181–82
drug use career, 30, 31
drug use progression, 31–37
  cessation and recovery, 35
    in treated populations, 36
    in untreated populations, 36
    recovery influencing factors, 37
  consequences of use, 34
  initiation and progression, 32
  persistent use, 33
DSM, 16. *See* Diagnostic and Statistical Manual of Mental Disorders
DSM-IV criteria, 17, 18

EMCDDA. *See* European Monitoring Centre on Drugs and Drug Addiction
enhanced/event based multipliers method, 127
epidemiologic approach model, 179
epidemiology, 8–11, 17–20
  analytic, 10–11
  archival data, use of, 63–76
  descriptive, 9–10
  ethical considerations, 145–55
  evidence-based response, 165
  in global context, 162
  population surveys, 99–106
  prevalence estimation methods, 113–28
  qualitative methods in, 133–42
  sampling issues in, 79–96
  use and abuse treatment data and, 226–27
estimation. *See* prevalence estimation
ethical challenges in drug use
  challenges in developing countries, 154
  free and informed consent, 151
  privacy, confidentiality and legal hazard, 153, 154
  safety issues, 154
ethics
  ethical principles, 148–51
    autonomy, 148
    beneficence, 149
    justice, 149
    non-maleficence, 149
  human biomedical research considerations, 149–51
  importance in drug use, 147
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 168, 173
European School Project on Alcohol and Drugs (ESPAD), 167
extrapolation, 126

family risk factors and drug abuse, 186
focus groups, 138. *See also* qualitative methods
free and informed consent
  human biomedical research based ethical issues, 149
  impaired consent issue, 152
  issues in drug use epidemiology, 151
  research participant payment issues, 152

gamma-butyrolactone (GBL), 69
gamma-hydroxybutyrate (GHB), 69
gatekeepers, 140
gender differences, drug use and, 37
Global Assessment Programme (GAP), 172
global context, drug epidemiology in, 162

haphazard sample, 84
health-related consequences of drug use, 50
heroin, 18, 33, 163
heterogeneity, 15–17, 19
hidden population surveys, 105
high risk
  population surveys, 105
  samples, 183

HIV, 172, 194
  infection among IDU, 194–96
  prevention among IDU, 196–99
    community/street outreach programs, 197
    effective programs for reducing risk behavior, 196
    slong-term drug abuse treatment programs, 199
    syringe exchange programs, 198
  prevention programs among IDU, 199–203
  rapid HIV transmission, 194, 195
  risk reduction, limitations of, 200
    HIV epidemics prevention aspects, 200
    HIV prevalence epidemics controling, 201
    sexual transmission, prevention of, 202
  transmission to non-injecting partner, 202
Home Office Addict Notification Index, 168
human biomedical research, ethical requirements of, 149–51
  free and informed consent, 149
  independent ethical review of risks and benefits, 149
  privacy and confidentiality, 150
  vulnerable research participants, 150

ICD. *See* International Classification of Diseases
IDU, 194
  HIV infection among, 194–96
  HIV prevention among, 196–99, 199–203
  HIV risk reduction limitations, 200–202
illness career concept, 31
indirect estimation methods, 116–27. *See also* qualitative methods
  back-calculation method, 127
  capture recapture method, 122–25
  enhanced/event based multipliers method, 127
  multiplier methods, 120–22
  synthetic estimation method, 126
  Truncated Poisson method, 126
inferences
  non-statistical, 86
  statistical, 86
informed consent. *See* free and informed consent
International Classification of Diseases, 16
international organizations and drug control, 172
interpersonal relationships related drug use consequences, 54
interviewing, 137
  group interview, 138
  quantitative versus qualitative interviews, 137
  semi-structured, 137

justice principle, 149

life course concept, 31
life histories, 138
Lisbon Consensus, 173

marijuana, 18, 33
mental health-related consequences of drug use, 51
methamphetamine, 33
minority samples, 184
Monitoring the Future Survey (MTF), 217
MRI, 5
multi-indicator models, 171
multiplier method, 120–22. *See also* capture recapture method

National Institute on Drug Abuse (NIDA), 72, 213, 215–17, 230
NHSDA, 231
nomination methods, 90. *See also* referral sampling techniques
non-maleficence principle, 149
non-probabilistic samples, 85
non-statistical inferences, 86
NSDUH, 231

OAS/CICAD, 167
observations, 139. *See also* interviewing

PDU. *See* problem drug users
personality approach model, 180
PET, 5
physiological problems, 5
Pompidou Group (PG), 168, 171
population surveys, 99–106
  general, 100
  high risk and hidden, 105
  needs and challenges, 106
  special, 101–5
    campus surveys, 103–5
    school surveys, 101–3
prevalence estimation, 87, 113–28
  direct methods for, 115
  indirect estimation methods, 116–27
    back-calculation method, 127
    capture recapture method, 122–25

enhanced/event based multipliers method, 127
equi-probable sampling assumption, 118
matching definition assumption, 118
multiplier methods, 120–22
population stability assumption, 118
source conditional independence, 118
synthetic estimation method, 126
Truncated Poisson method, 126
indirect methods for, 115
key areas of
key targets monitoring, 115
public health surveillance/epidemiology, 115
service planning and resource allocation, 114
privacy based ethical issues, 150, 153
problem behavior approach model, 180
problem drug users (PDU), 116
protective family factors and drug abuse, 187
psychopathology approach model, 181
psychopharmaceutical drug, 17
public health, drug epidemiology and, 165

qualitative methods, 133–42. *See also* indirect estimation methods
qualitative inquiries of drug use, 135
qualitative research background, 136–42
focus groups, 138
interviewing, 137
multiple data collection techniques and triangulation, combining of, 140
observations, 139

racial/ethnic differences, drug use and, 38
random sampling, 81, 84, 85, 86, 88, 89, 91, 93, 94
referral sampling techniques
chain referral sample, 93–94
snowballing, 91–93
regional cooperation initiatives involved with drug control, 172
Rohypnol, 9

SAMHDA, 228
SAMHSA, 17, 18
sample, definition of, 80
sampling issues (epidemiological methods), 79–96
behavioral measuring definitions, 81
general population frame usefulness, 82
non-standard sampling frames, use of, 84
school surveys, 83
good practice recommendations, 94
incomplete lists of drug abusers, 87
site sampling aspects, 88–89
specialist prevalence estimation methods, 87
study population, re-defining of, 88
inferences, sampling control, biases and errors, 84
non-probabilistic samples, 85
statistical and non-statistical inferences, 86
move from standard to innovative sample selection procedures, 81
nomination methods, 90
referral sampling techniques
chain referral sample, 91, 93–94
snowballing, 91–93
school surveys, 101–3. *See also* campus surveys
usefulness of, 83
SEER. *See* Surveillance, Epidemiology, and End Result data
self-control models, 181
site sampling, 88–89
snowball sampling, 91–93. *See also* chain referral sample
social adaptation approach model, 179
social learning models, 182
SPECT, 5
statistical inferences, 86
substance abuse
and heterogeneity, 15–17
multifinality, 20
substance use and abuse, treatment data use and. *See also* drug use and abuse
conceptual framework, 226–27
integration with data sources, 230–32
treatment populations, 227–30
Surveillance, Epidemiology, and End Result data, 64
survey. *See* population surveys
synthetic estimation method, 126
syringe exchange programs, 198

technical networks involved with drug control, 172
temperament models, 181
“thick description”, 140

transmission of HIV among IDUs, 194
treatment data. *See under* substance use and abuse
Treatment Outcome Prospective Study (TOPS), 227
triangulation, 141
Truncated Poisson method, 126

UNAIDS, 172
UNGASS, 1998, 166
UNODC, 170, 172
UNODCP, 173
use and abuse. *See* drug use and abuse

waves, 93
Woodlawn Project, 179
World Health Organization (WHO), 172

'zero stage sample', 91
zero wave procedure, 93